Publications
Filter by type:
Edith Szafer-Glusman, Franklin V. Peale Jr., Guiyuan Lei, Anja Mottok, Pedro Farinha, Jill Ray, Thalia A. Farazi, Martin Kornacker, Mikkel Z. Oestergaard, Juan Liu, Randy D. Gascoyne, Elizabeth Punnoose.
BCL2 Expression Identifies a Population with Unmet Medical Need in Previously Untreated (1L) Patients with DLBCL.
In
Blood,
2017.
Source Document
L.H. Sehn, M.Z. Oestergaard, M. Trněný, A. Bosi, M. Egyed, A. Illes, H. Nakamae, S. Opat, M. Topp, F. Zaja, G. Fingerle‐Rowson, G. Lei, T. Nielsen, E.A. Punnoose, M. Rahman, J. Ray, L. Zhang, M. Martelli, U. Vitolo.
Prognostic impact of BCL2 and MYC expression and translocation in untreated DLBCL: results from the phase III Goya study.
In
Hematological Oncology,
2017.
Source Document
Elizabeth Punnoose, Franklin V. Peale Jr., Guiyuan Lei, Thomas Sandmann, Richard Bourgon, Edith Szafer-Glusman, An Do, Randy D. Gascoyne, Gilles A. Salles, John F. Seymour, Marek Trneny, Laurie H. Sehn, F. Javier Munoz, Kirsten E. Mundt.
Prevalence and Prognostic Value of BCL2 and MYC Protein Expression within ABC and GCB Subtypes in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma: Analysis from the Phase III MAIN Study.
In
Blood,
2015.
Source Document
Guillaume Cartron, Sophie de Guibert, Marie-Sarah Dilhuydy, Franck Morschhauser, Veronique Leblond, Jehan Dupuis, Beatrice Mahe, Reda Bouabdallah, Guiyuan Lei, Michael Wenger, Elisabeth Wassner-Fritsch, Michael Hallek.
Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.
In
Blood,
2014.
Source Document
Jianmei Wang, Adam Platt, Ruchi Upmanyu, Søren Germer, Guiyuan Lei, Christina Rabe, Ryma Benayed, Andrew Kenwright, Andrew Hemmings, Mitchell Martin, Olivier Harari.
IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis.
In
BMJ Open,
2013.
Source Document
Radford J, Davies A, Cartron G, Morschhauser F, Salles G, Marcus R, Wenger M, Lei G, Wassner-Fritsch E, Vitolo U.
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
In
Blood,
2013.
Source Document
Salles GA, Morschhauser F, Solal-Céligny P, Thieblemont C, Lamy T, Tilly H, Gyan E, Lei G, Wenger M, Wassner-Fritsch E, Cartron G.
Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study.
In
Journal of Clinical Oncology,
2013.
Source Document
Morschhauser FA, Cartron G, Thieblemont C, Solal-Céligny P, Haioun C, Bouabdallah R, Feugier P, Bouabdallah K, Asikanius E, Lei G, Wenger M, Wassner-Fritsch E, Salles GA.
Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study.
In
Journal of Clinical Oncology,
2013.
Source Document